Global Thalassemia Market Global Thalassemia Market Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) The "Global Thalassemia Market (2023-2028) by Type, Disease Type, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive overview and detailed insights into the global thalassemia market. It covers data and analysis related to thalassemia prevalence, treatment methods, market s
/PRNewswire/ The "Global Thalassemia Market (2023-2028) by Type, Disease Type, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff.
Global Melphalan Market Size, Status and Forecast 2021-2028
amiFebruary 13, 2021 36
Melphalan is a medication which can be given as an injection through a vein and is also available in tablet form. The drug comes as a white tablet which is taken while the stomach is empty and the tablets needs to be stored in a cool place. The duration of therapy depends on the types of medications patients take, how well the body reacts to them, and the type of cancer the patient is having. The drug is majorly used for cancer treatment but the physicians also prescribe the drug for treatment of other diseases. The amount of drug to be prescribed depends on various factors such as height and weight of the patient and also considers general health problems of the patient. Presently Melphalan is available in the United States market in the form of capsules as well as injection. There are many suppliers as well as distributors currently active in the market. The Melphalan drug manufacturing compani
E-Mail
(Boston) Atrial fibrillation (AF) is associated with a higher risk of complications including ischemic stroke, cognitive decline, heart failure, myocardial infarction and death. AF frequently is undetected until complications such as stroke or heart failure occur.
While the public and clinicians have an intense interest in detecting AF earlier, the most appropriate strategies to detect undiagnosed AF and medical prognosis and therapeutic implications of AF detected by screening are uncertain.
A new report led by Boston University School of Medicine (BUSM) researcher Emelia J. Benjamin, MD, ScM, builds upon a recently conducted National Heart, Lung, and Blood Institute s virtual workshop that focused on identifying key research priorities related to AF screening.